Potrelease TR Tablet Drug Interactions

The following drug interactions and/or related problems have been selected on the basis of their potential clinical significance (possible mechanism in parentheses where appropriate: not necessarily inclusive).
Note: Combinations containing any of the following medications, depending on the amount present, may also interact with this medication.
Adrenocorticoids, glucocorticoids, especially with significant mineralocorticoid activity, or Corticotrophin (ACTH): concurrent use of these medications may decrease effects of potassium supplements on serum potassium concentrations, close monitoring of serum potassium concentration is recommended.
Antimuscarinics, especially atropine and related compounds: concurrent use with potassium chloride oral supplements, especially those with wax matrix, may increase severity of gastrointestinal lesions produced by potassium chloride alone; patients should be carefully monitored endoscopically for evidence of lesions.
Blood from blood bank: may contain up to 30 mEq of potassium/liter of plasma or up to 65 mEq/liter of whole blood when stored for more than 10 days or;
Diuretics, potassium-sparing, such as amiloride, spironolactone, or triamterene, or;
Low-salt milk: may contain up to 60 mEq of potassium/liter or;
Potassium-containing medications, other, or Salt substitutes: most contain substantial amount of potassium; concurrent administration with potassium supplements tends to promote serum potassium accumulation with possible resultant hyperkalaemia, especially in patients with renal insufficiency.
Calcium salts: parenteral administration antagonizes the cardiotoxicity of hyperkalaemia; calcium should be used cautiously in patients receiving potassium and digitalis medications because of the danger of precipitating cardiac arrhythmias.
Captopril: concurrent administration may result in hyperkalaemia since reduction of aldosterone production induced by captopril may lead to elevation of serum potassium.
Digitalis glycosides: potassium supplements are not recommended for concurrent use in digitalized patients with severe or complete heart block; however, if potassium supplements need to be used to prevent or correct hypokalaemia in digitalized patients, carefully monitoring of serum potassium concentrations is extremely important to avoid hyperkalaemia, which is very dangerous in digitalized patients.
Exchange resins, sodium cycle, such as sodium polystyrene sulfonate: whether administered orally or rectally, serum potassium concentrations are reduced by sodium replacement of the potassium; fluid retention may occur in some patients because of the increased sodium intake.
Glucose-insulin infusion or Sodium bicarbonate infusion: serum potassium concentrations are reduced by promoting a shift of potassium ion into the cells.
Laxatives: chronic use or overuse of laxatives may reduce serum potassium concentrations by promoting excessive potassium loss from the intestinal tract.
Quinidine: concurrent use with potassium supplements usually enhances quinidine's antiarrhythmic effects.
Vitamin B12: extended-release dosage forms of potassium may reduce absorption of vitamin B12 from gastrointestinal tract, thus increasing requirement for vitamin B12.